Business Wire

Pharnext to Present Phase 2 Data From PXT864 at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, United States

Del

Regulatory News:

Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that Phase 2 clinical trial data related to PXT864, a PLEODRUG® developed for the treatment of Alzheimer’s disease (AD), will be presented at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) conference, December 8-10, 2016 in San Diego (United States).

Details are as follows:

Date

 

Time

 

Event

Friday

December 9

      Poster Session 2, P2-12

 

Neurophysiological Effect of PXT864 in mild Alzheimer’s Disease Patients

 

Presenter:

Karim Bennys, MD, Memory Research Resource Center for Alzheimer’s disease, University Hospital, Montpellier, France

Saturday

December 10

  7:30 am   Oral Communications Sessions, OC 54

 

36 Weeks of Treatment with PXT864 in Mild Alzheimer’s disease: Results from the PLEODIAL Extension Study

 

Presenter:

René Goedkoop, MD, Chief Medical Officer, Pharnext, Issy-les-Moulineaux, France

Safety and clinical efficacy of PXT864 were assessed in 45 treatment-naïve patients with mild AD in a multicenter, exploratory, single blind Phase 2 study (PLEODIAL-I). Three doses of PXT864 were administered for 4 weeks followed by 4 weeks of placebo and then a 4-week re-challenge with PXT864. Subjects were then invited to continue study treatment (same dose received in PLEODIAL-I) for a further 24 weeks in the PLEODIAL-II extension study. Patients were treated with PXT864 for 32 out of 36 weeks in the PLEODIAL-I and II studies, and were allowed to use donepezil 5 mg, if their condition warranted treatment with a symptomatic agent, during the last 12 weeks of the study.

PXT864 is a novel synergic fixed combination of baclofen and acamprosate given orally as a capsule twice a day. PXT864 was developed to restore the disrupted excitatory – inhibitory balance in the brain of patients suffering from neurodegenerative diseases (disrupted by toxic factors such as Aβ oligomeric peptides in Alzheimer’s disease). PXT864’s most advanced target indication is Alzheimer’s disease. Development in other neurodegenerative diseases including Parkinson’s disease and amyotrophic lateral sclerosis (ALS) are also planned.

About Alzheimer’s Disease
Alzheimer’s disease is an irreversible, progressive neurodegenerative dementia. It is characterized by neuronal death in brain structures implicated with memory leading to cognitive deficits such as thinking, memory, personality and behavior disorders. The disease typically develops and worsens gradually over the course of several years and ultimately leads to death. It affects around 25 million people worldwide. Unfortunately, three out of four patients are diagnosed once the disease is at a severe stage. Alzheimer's disease has no cure and current existing therapies provide only short and modest symptomatic relief.

About Pharnext
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY®. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG® offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

PLEODRUG® and PLEOTHERAPY® are registered trademarks by Pharnext.

Contact information

Pharnext
Pierre Schwich, +33 (0)1 41 09 22 30
Chief Financial Officer
investors@pharnext.com
or
Investors Relations
NewCap
Julie Coulot, +33 (0)1 44 71 20 40
pharnext@newcap.eu
or
Media Relations (Europe)
Alize RP
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (US)
Russo Partners
Tony Russo, Ph.D.
+1 212-845-4251
tony.russo@russopartnersllc.com
or
Matt Middleman, M.D.
+1 212-845-4272
matt.middleman@russopartnersllc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Bidgely Closes $27M Series C to Grow Artificial Intelligence Solution for Utilities and Energy Retailers16.1.2018 11:00Pressemelding

U.S.-based Bidgely announced today the closing of a $27 million Series C round of financing, marking the largest round of investment to date for any energy disaggregation technology. Georgian Partners, an investment fund known for its focus on high-growth enterprise software companies that use applied artificial intelligence to disrupt markets, led the oversubscribed round. Returning investors include Khosla Ventures, E.ON, and innogy. Constellation Technology Ventures, the venture capital arm of Exelon Corporation, is also expected to return. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005615/en/ Bidgely Energy Usage Itemisation (Photo: Business Wire) “We invest in high-growth SaaS companies that are applying AI to solve real-world business problems,” said Simon Chong, Managing Partner at Georgian Partners. “Bidgely is using machine learning to fundamentally reinvent customer engagement with utilities and enable a n

Glennmont Seeks More Than 500MW of Investment Opportunities in Clean Energy Infrastructure Assets with Expanded Investment Capacity16.1.2018 10:19Pressemelding

Glennmont Partners has expanded its investment capacity in the clean energy infrastructure space and now has three funds under management – these are Fund I (2010) and Fund II (2013), which are fully invested, and now a new third Fund (2017). Opportunities are being sought for a portfolio of clean energy infrastructure projects in Europe. Glennmont is one of Europe’s largest investors focusing exclusively on investment in clean energy infrastructure. This announcement follows the successful refinancing of Glennmont’s 245MW Italian wind portfolio in October and the refinancing of the Sleaford straw-fired biomass plant in September - amounting to around €340m of capital raised over the course of 2017. Glennmont’s strategy remains consistent with its past experiences: it seeks to invest in solar PV, offshore and onshore wind, bioenergy and small-scale hydro across the EEA; it will target to-be-built and recently operational assets with stable, predictable cash yields underpinned by regula

Breed Reply Portfolio of IoT Start-Ups Raise in Excess of $50 Million in Series A Funding in 201716.1.2018 10:00Pressemelding

Breed Reply, a leading operational investor in early-stage internet of things (IoT) businesses, saw one third of its 18-strong portfolio of investee companies, complete series A funding rounds in 2017. In total, six companies raised in excess of $50 million during the year with funds coming from notable investors including Accel, Aviva Ventures, Finance Wales, Intu and MunichRE. More companies in the growing portfolio are expected to be ready for Series A investment in 2018. The successful companies span a broad range of IoT sectors: Callsign (Cyber Security); Cocoon (Smart Home); enModus (Smart Building); Senseye (Industrial); WePredict (Big Data); and Zeetta Networks (Platforms). Helping start-ups prepare for future funding is a crucial part of Breed Reply’s commitment to companies when it invests. As an active operational investor, Breed Reply works closely with management to accelerate the company’s development to achieve Series A funding and beyond. The team has significant experi

Japan's 16 Most Mesmerizing Destinations Introduced in a New Live-Action 360-Degree Video16.1.2018 10:00Pressemelding

Japan National Tourism Organization (JNTO, London Office) released a 360-degree VR video “[360-degree VR] JAPAN – Where tradition meets the future” on 16 January 2018. The video visualizing the essence of Japan and its culture was created as part of “JAPAN – Where tradition meets the future”, a large-scale inbound tourism promotion targeting 15 European countries, which started in 2016. With the concept of fusing together “tradition,” “innovation,” and “nature” which coexist in the diverse culture of Japan, the 360-degree VR video takes viewers on a virtual tour of Japan. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005057/en/ Japan National Tourism Organization's large-scale inbound tourism campaign "JAPAN - Where tradition meets the future" (Photo: Business Wire) As part of the promotion, there will be a social media prize competition to win a round-trip to Japan. Also, an AR digital signage display “Interactive Vis

MagicStay Raises 1.5 Million Euros to Accelerate Its Development16.1.2018 10:00Pressemelding

The short-term rental start-up for business travelers MagicStay.com , has just finalized a new round of fundraising to continue its development. Just four years since its release, the rental platform already offers 150,000 apartments in 90 countries and has taken a leading position in the alternative accommodation industry. The fundraising totaling 1.5 million Euros was led by the start-up’s main shareholders (Michaël Benabou, Benoit Bassi, Patrick Lucas, Nicolas Quenedey or Charles Petruccelli, former CEO of American Express Global Business Travel...), as well as new investors, including Marc Frappier, Managing Partner of Eurazeo and Head of Eurazeo Capital, Thibault Basquin, Managing Director of Ardian, Nicolas Santi-Weil, CEO of AMI Paris... This round table will let the start-up accelerate its exclusive technological development for employees of large companies to book secure apartments as easily as hotel rooms, via either existing booking tools (Hotel Booking Tool, Self Booking To

Panasonic Launches New IoT Services with Silicon Valley Startups at CES 2018 Sands Expo16.1.2018 08:42Pressemelding

The Automotive & Industrial Systems Company of Panasonic Corporation is challenging to develop new businesses and services in the IoT field, in cooperation with Silicon Valley startups. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005839/en/ Panasonic booth at CES 2018 Sands Expo (Photo: Business Wire) [Video] One Touch Home Automation, One Touch ID Authentication | #PanasonicCES 2018 https://youtu.be/dNGulaV1Bx0 Panasonic is advancing the development of new IoT services and solutions by combining leading UI/UX(*1) technology with its strong HMI (human machine interface) design technology, which has been refined through the smartphone switch business and automotive touch panel business. To demonstrate this initiative, Panasonic set up a display booth at CES 2018 (Sands Expo), which took place in Las Vegas, Nevada, US from January 9 (Tuesday) to 12 (Friday), 2018. With the concept of "Touch by Panasonic," solutions fea

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom